Intraspinal TumorEURJMTNCT07056023
Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors
An observational study of Intraspinal Tumor and Juxtamedullary Tumor, run by University Hospital Muenster at 1 site in Germany.
Trial summary
Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary objectives: Assessment of variables leading to better outcome through regression analysis: 1. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intraspinal Tumor, Juxtamedullary Tumor
- How many people
- 100 participants
- Where
- 1 siteGermany
- Study dates
- 1 May 2025to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults, age ≥18 years, patients treated on intraspinal, extra medullary tumor
Who may be able to join
- Adult, age ≥18 years, patients treated on intraspinal, extra medullary tumor
- Patients must have sufficient cognitive and language skills to give informed consent
Who cannot join
- Absence of informed consent
- Lack of ability to consent
- Primary bone tumors invading the intra-spinal space
- Vertebral metastasis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Hospital Muenster
Münster, Nordrhien Westfalen, 48167
Michael schwake, MD, 02518343930, michael.schwake@ukmuenster.de
About this study
Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary objectives: Assessment of variables leading to better outcome through regression analysis: 1. Influence of surgical approach on functionality, pain, and quality of life 2. Comparison between patient with severe neurological (McCormick scale 3-5) to patients with mild deficits (McCormick scale 1-2) 3. Role of intraoperative monitoring (IOM) in extent of resection and neurological deficits Assessment of treatment variations: 1. Assessment of risk factors for incomplete resection 2. Non inferiority of unilateral approach to achieve gross total resection of spinal meningioma, schwannoma and cauda ependymoma 3. Role of bed rest after surgery to prevent cerebro-spinal fluid leakage 4. Influence of laminectomy on cerebro-spinal fluid leakage Quality indicators: assessments of length of hospital stay, 30- and 90-days re-admissions, 30- and 90-days re-surgery, nosocomial infections
Read the detailed description
Introduction
- Background information Juxta-medullary tumors are mostly benign tumors in the spinal canal that may cause neurological deficits due to spinal cord or nerve root compression. The knowledge about the natural course of the disease, optimal treatment regarding timing of surgery and surgical approach are based on case series from different institutions around the world. Moreover, little is known about the long-term clinical and functional outcome after tumor resection, indicators of quality of treatment and quality of life after surgery.
Main treatment option of juxta-medullary tumors is a neurosurgical resection. The main goal of the surgery is to decompress the neuro structures in order to reveal neurological deficits. However, achieving gross total resection (GTR) is important in order to achieve long progression free survival (PFS).
Therefore, the surgeon should choose the appropriate surgical approach to achieve these goals. Several publications show that GTR, whenever possible, is essential, as subtotal resection is the main reason of tumor regrowth or recurrence. Moreover, revision surgery due to tumor recurrence is one of the main risk factors of unfavorable outcome, probably to intradural adhesions, related to the first procedure. Due to the mostly benign nature of juxtamedullary tumors, it would be very difficult to evaluate overall survival (OS) and progression free survival (PFS) within this progressive registry in the short run. For this reason, data should be kept for late cohort analysis after longer intervals. Probably up to 20 years, as previous publications reported recurrence of spinal meningioma after GTR 10 years or more after surgery.
On the other hand, too large exposure may lead to impaired recovery after surgery, eventual higher blood loss during surgery and thus longer stay in hospital (LOS) and impaired quality of life. Moreover, extensive bone resection may lead to spinal instability requiring instrumentation, during index surgery or during further follow up in case of postoperative deformity).
In addition to the oncological outcome, the neurological outcome is also very important. Depending on the localization of the tumor, its form and compression of intra-spinal structures such as the spinal cord or nerve roots many patients develop neurological deficits. Besides GTR the other goal of resection is the neurological recovery of these patients. Previous reports show that the time point of surgery is important in order to achieve full recovery. However, most of the data is derived from retrospective case series. One of the aims of this registry is to prove this hypothesis. These neurological deficits are, as mentioned above, related to the localization of the tumor within the spine, Tumors in the cervical spine would cause mainly gait ataxia, spasticity, and weakness in the upper extremities while tumors in the lumbar spine would lead to deficits in the lower extremities in combination to disturbances of bladder, bowl, and sexual functions. These functions should be evaluated and monitored, before and after treatment.
Other concerns are safety requirements in order to prevent peri-operative complications. For example, the role of intra-operative neurophysiological monitoring. Some authors recommend the utilization intra operative monitoring, however, the evidence level is very low. Other open questions are for example the utility of microscope, methods for dura closure and thrombosis prevention.
On the other hand, some tumors can be treated with irradiation, some studies showed efficacy of this method mainly in the case of Schwannomas and meningiomas. In case of residual tumor or tumor progression irradiation can be also performed to prevent further growth.
Lastly, in comparison to the methods mentioned above, a wait-and-see approach can be used for asymptomatic patients or those with mild symptoms. In this case, clinical and imaging examinations are performed at regular intervals to check the neurological status and the tumor. This can also be done for longer periods of time because of the benign nature of these tumors with the slow growth. in case of new neurological deficits of or progression surgical treatment should be advocated. Overall, it is not certain at what point therapy is indicated, especially in asymptomatic patients. Because many of these tumors are discovered by coincidence during imaging, which was performed due to other symptoms.
2 Rationale of the study The rationale of the trial is to define benchmarks on quality of life, functionality and neurological outcome after resection of juxtamedullary tumors. Furthermore, to assess and define benchmarks of quality indicators of the treatment. These measurements would be essential for future studies.
Further rationales are to find out the optimal timing, method, and approach to treat juxta-medullary tumors. Because of the low incidence of juxta-medullary tumors, a multi-center trial seems to be essential. This would allow us to analyze a large number of patients, much more than any other published paper. Moreover, the different protocols and standards approaches in each center would allow conducting Comparative Effectiveness Research (CER).
3 Aims The goal of this study is to establish a multicenter cohort of patients operated on juxtamedullary tumors. With especial emphasis on functional outcome, quality indicators (QI) and quality of life after surgery three months after surgery. Causes of unfavorable outcome should be determined.
The main hypothesis is that early and less-invasive surgery with maximal extents of resection would lead to a more favorable outcome. In the future the registry would help assessing further hypothesis can be answered on the base of comparative effectiveness research (CER), examples of these hypothesis are:
- Functional and neurological outcome in comparison to preoperative status. Comparison between Panties with good preoperative McCormick score (1-2) and those with a high preoperative score (3-5).
- Risk-factors for non-favorable outcome
- Non-Inferiority to achieve gross total resection via unilateral approaches
- Question whether laminectomy as approach may cause mor pain and impact quality of life
- Risk factors for the development of CFS Leaks
- Does bed rest prevent CSF leaks
- Does laminectomy elevate the risk of CSF leaks
- Does the utility of intraoperative neurophysiological monitoring (IOM) influence surgical outcome: rate of GTR and neurological outcome
- Rate of postoperative kyphosis and deformity in laminectomy in comparison to non-laminectomy
- Is facetectomy required for GTR of dumbbell tumors?
- Risk factors for non-complete resection
Primary outcomes are determined by:
Quality of life based on the questionnaire (EQ-D5) Extent of tumor resection (see CRF): according to surgeon: 1. Meningioma: Simpson grade 1 and 2 2. Schwannoma: complete resection, including nerve root 3. Cauda ependymoma: complete resection, including filum terminale according to postoperative MRI, 3 months after surgery 4. Other: surgeon's decision Neurological status (McCormick Score) (see CRF), 3 months after surgery Secondary Outcome Imaging: preoperative and postoperative MRI Volumetry Spinal canal occupancy ratio in %
Further patient reported outcomes:
Functionality: Neck disability index (NDI) for tumors in the cervical spine, Oswestry disability index (ODI) for tumors in the thoracic and lumbar spine (see CRF) Local and radicular pain (VAS 1-10) (see CFR) Neurological status: motor function of each limb, ataxia and gait (mJOA score) (see CRF) HADS score- based score for anxiety Questionnaire on bladder, bowl, sexual functionality
Quality indicators (QI):
Length of hospital stay 30- and 90-days readmission Nosocomial infections Blood loss Duration of surgery Progression of the disease or recurrence Other adverse events Mortality Assessment of adverse events according to Common Terminology Criteria for Adveres Events (CTCAE) 5.0 and severity according to the Ibañez scale (see CRF) CSF leakage is defined as one, when CSF leakage is identified on imaging of clinicaly and treatment is required: operative or conservative (Lumbar drain for example) Postoperative kyphosis of deformity is defined, when symptomatic (for example pain) or evident on imaging (for example kyphotic fracture on MRI) Methodology All patients treated in one of the study centers are recorded in a databank (Redcap, see below), which includes information about admission, symptoms, other diseases, treatment, quality indicators and questionnaires regarding quality of life and functionality. Data should be recorded in an anonymized in each center (see below).
For the analysis the CRF includes information about admission, surgery, discharge, and 3 months (90 days) after surgery. In addition, patients should fill out questionnaires on quality of life (EQ-D5) and functionality (ODI or NDI). Later, yearly visits can be completed to have long term results in the future regarding progression free survival (PFS) and overall survival (OS). The CRF is attached to this document.
Univariate and multivariate statistics would be applied to prove which variables might lead to a favorable or unfavorable outcome.
A minimum number of one hundred (N=100) inclusions seems to be adequate in order to perform reasonable analysis. In the event of nonsufficient recruitment, results and further recruitment would be discussed two years after initiation of the study, and annually thereafter.
- Conditions
- Intraspinal Tumor, Juxtamedullary Tumor
- Keywords
- intra-dural tumors, spinal meningioma, spinal schwannoma, spinal ependymoma
- Medical subject headings
- Spinal Cord Neoplasms, Meningioma
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of life based on the questionnaire
The EuroQol 5-Dimension questionnaire (EQ-5D) is a standardized measure of health-related quality of life. It includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each rated on 3 or 5 levels, and a visual analogue scale (EQ VAS) from 0 (worst health imaginable) to 100 (best health imaginable). Higher EQ VAS scores indicate better health status. The descriptive system can also be converted to an index score ranging typically from <0 (worse than death) to 1 (perfect health), where higher values reflect better health.
Measured: prior and 3 months after resection
Extent of tumor resection
- Meningioma: Simpson grade 1 and 2 2. Schwannoma: complete resection, including nerve root 3. Cauda ependymoma: complete resection, including filum terminale according to postoperative MRI, 3 months after surgery 4. Other: surgeon's decision
Measured: 3 months after resection
Neurological status
The McCormick Functional Classification Scale for Spinal Cord Tumors assesses functional impairment in patients with intramedullary spinal tumors. It ranges from Grade I (minimal symptoms, fully active) to Grade IV (severe disability, dependent). The scale has four grades, with Grade I as the best and Grade IV as the worst outcome. Higher grades indicate greater neurological impairment and reduced functional independence.
Measured: prior to surgery and 3 months after surgery
Secondary outcomes (23)
Tumor Volume
The Tumor Volume on MRI Scans measures the three-dimensional size of a tumor using magnetic resonance imaging. It is typically calculated by multiplying tumor dimensions (length × width × height) and applying a correction factor (e.g., ×0.5 for ellipsoid shapes). Volume is expressed in cubic millimeters (mm³) or centimeters (cm³). There is no fixed minimum or maximum, as values depend on tumor size
Measured: prior to surgery and 3 months after surgery
Spinal Canal Ratio
The Spinal Canal Ratio (also called the Spinal Canal Occupation Ratio) quantifies spinal canal narrowing, typically in cases of spinal stenosis or tumors. It is calculated as the ratio of the space occupied by the lesion (e.g., tumor or disc) to the total area of the spinal canal on axial imaging. Values range from 0 (no compression) to 1 (100% occupation of the canal). Higher values indicate worse outcomes, reflecting more severe canal compromise and potential cord compression.
Measured: prior surgery and 3 moths after surgery
Functionality: Oswestry disability index (ODI) for tumors in the thoracic and lumbar spine
The Oswestry Disability Index (ODI) is a patient-reported questionnaire used to assess disability due to lower back pain. It includes 10 sections covering pain intensity and functional limitations (e.g., walking, lifting, sleeping), each scored from 0 to 5. The total score is converted to a percentage from 0% (no disability) to 100% (maximum disability). Higher scores indicate worse outcomes, reflecting greater functional impairment. The ODI is widely used to evaluate treatment effectiveness and monitor progress in patients with spinal disorders.
Measured: prior and 3 months after surgery
Funtionality: Neck disability index (NDI) for tumors in the cervical spine
The Neck Disability Index (NDI) is a validated, patient-reported questionnaire used to measure self-rated disability related to neck pain. It includes 10 items covering pain intensity and daily activities (e.g., personal care, lifting, concentration), each scored from 0 to 5. The total score ranges from 0 to 50, which is often expressed as a percentage (0% to 100%), where 0 indicates no disability and 100 indicates complete disability. Higher scores represent worse outcomes, reflecting greater functional impairment due to neck pain.
Measured: prior surgry and 3 months after surgery
Local and radicular pain
The Visual Analogue Scale (VAS) is a simple and widely used tool to measure subjective experiences such as pain intensity. Patients rate their pain on a continuous scale from 0 to 10 or 0 to 100, with 0 representing "no pain" and the maximum value (10 or 100) indicating the "worst pain imaginable." Higher scores reflect worse outcomes, corresponding to greater pain severity. The VAS is quick to administer and sensitive to changes over time, making it useful for monitoring treatment effects.
Measured: prior and 3 months after surgery
Neurological status
Motor, sensory, ataxia, and gait disturbances are recorded as yes or no.
Measured: prior and 3 months after surgery
Motor deficits
The Medical Research Council (MRC) Scale for Muscle Strength is a standardized tool used to grade muscle power in patients with motor deficits. Each muscle group is scored from 0 to 5, where 0 indicates no muscle contraction and 5 indicates normal strength. The total score can range from 0 to 5 per muscle group, with higher scores indicating better outcomes and less motor impairment. The scale is widely used in neurology and rehabilitation to assess and monitor motor function over time.
Measured: prior surgery and 3 months after surgery
anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire used to screen for symptoms of anxiety and depression in medically ill patients. It consists of 14 items, split into two subscales: HADS-A (anxiety) and HADS-D (depression), each ranging from 0 to 21. Each item is scored from 0 to 3. The total HADS score ranges from 0 to 42, with higher scores indicating worse outcomes, i.e., greater psychological distress. Scores ≥8 on either subscale suggest clinically relevant symptoms. HADS does not assess motor deficits.
Measured: prior and 3 months after surgery
bladder functionality
questionaire on functionality:
Sensation in the "saddle" area (buttocks, medial hips)
- Normal
- Paresthesia
- Reduced sensation
- Absent sensation
Bladder function:
- Normal function
- Mild dysfunction (occasional incontinence, but mostly continent)
- Moderate dysfunction (frequent incontinence, but some control)
- Severe dysfunction (total incontinence)
Measured: prior and 3 months after surgery
Bowl functionality
The Low Anterior Resection Syndrome (LARS) Score is a validated questionnaire used to assess bowel dysfunction after low anterior resection for rectal cancer. It includes 5 items covering incontinence, frequency, clustering, urgency, and gas control. Each response has a weighted score, with a total score ranging from 0 to 42. Scores are classified as No LARS (0-20), Minor LARS (21-29), or Major LARS (30-42). Higher scores indicate worse outcomes, reflecting more severe bowel dysfunction and impact on quality of life.
Measured: prior surgery and 3 months after surgery
Sexual funtionality
Questionaire:
Males
- Normal erectile and ejaculatory function
- Mild erectile or ejaculatory dysfunction (able to have intercourse with mild difficulty)
- Moderate erectile or ejaculatory dysfunction (intercourse possible with significant difficulty or partial erection)
- Severe erectile or ejaculatory dysfunction (intercourse rarely or not possible)
- Complete loss of erectile and ejaculatory function Females
- Normal sexual function
- Mild dysfunction (decreased arousal or lubrication, but able to have intercourse) Moderate dysfunction (significant difficulty with arousal or lubrication, painful intercourse)
- Severe dysfunction (intercourse rarely or not possible due to dysfunction)
- Complete loss of sexual function
Measured: prior and 3 months after surgery
Length of hospital stay
Length of hospital stay in days after asurgery. Day 0 is day of surgery
Measured: Perioperative/Periprocedural
30-days readmission
Whether the patient was admitted to the hospital within 30 days after surgery
Measured: 3 months after surgery
90-days readmission
Whether the patient was admitted to the hospital within 30 days after surgery
Measured: 3 months after surgery
Nosocomial infections
Whether the patient had a nosocomial infection after surgery. A nosocomial infection, also known as a hospital-acquired infection (HAI), is an infection that develops 48 hours or more after hospital admission or within 30 days after receiving healthcare, which was not present or incubating at the time of admission. Common types include pneumonia, urinary tract infections, surgical site infections, and bloodstream infections. These infections often involve antibiotic-resistant organisms and can increase morbidity, mortality, and healthcare costs.
Measured: Perioperative/Periprocedural and 3 motnhs after surgery
estbimated blood loss
The Estimated Blood Loss (EBL) During Surgery is a clinical measure used to approximate the volume of blood a patient loses during an operation. It is typically recorded in milliliters (mL), based on visual assessment, suction canister volume, and gauze saturation. There is no fixed minimum or maximum, but values can range from a few milliliters to several liters, depending on the procedure. Higher EBL values indicate worse outcomes, as they may reflect surgical complexity, increased risk of transfusion, and postoperative complications.
Measured: Perioperative/Periprocedural
Duration of surgery
Duration of surgery in minutes
Measured: Perioperative/Periprocedural"
Progression of the disease or recurrence
tumor growth visible on MRI
Measured: 3 months after surgery
adverse events
adverse events not mentioned in the protocol should be also recored. The Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 is a standardized classification system developed by the U.S. National Cancer Institute to document and grade the severity of adverse events (AEs) in clinical trials. It includes over 800 terms covering organ systems, symptoms, and lab abnormalities. Each adverse event is graded from Grade 1 (mild) to Grade 5 (death related to AE). CTCAE ensures consistent reporting, supports safety monitoring, and facilitates comparison of safety profiles across studies.
Measured: 3 months after surgery
Mortality
death of patients within 90 days after surgery
Measured: 3 months after surgery
advers events _2
The Ibañez Scale is a classification system used to grade adverse events and complications following spinal surgery. It categorizes complications based on their severity and the need for intervention, helping to standardize outcome reporting. The scale ranges from Grade I (minor, requiring no treatment) to Grade IV (life-threatening or resulting in death). It allows clinicians to objectively assess and compare postoperative morbidity, supports clinical decision-making, and improves transparency in surgical outcome reporting.
Measured: Perioperative/Periprocedural and 3 months after surgery
CSF leakage
CSF leakage is defined as one, when CSF leakage is identified on imaging of clinicaly and treatment is required: operative or conservative (Lumbar drain for example)
Measured: Perioperative/Periprocedural and 3 months after surgery
Postoperative kyphosis
Postoperative kyphosis of deformity is defined, when symptomatic (for example pain) or evident on imaging (for example kyphotic fracture on MRI)
Measured: 3 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start1 May 2025
- Primary completionJun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraspinal TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Muenster
- Sponsor type
- University, hospital or other
- Collaborators
- Technical University of Munich, University Hospital Freiburg, Medical University of Cologne, Universitätsklinikum Hamburg-Eppendorf
- Responsible party
- Principal investigator, Michael Schwake, University Hospital Muenster
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07056023
- Sponsor's protocol ID
- EURJMT
- Acronym
- EURJMT
- Status last verified
- Jul 2025
- First submitted
- 19 May 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors
- ClinicalTrials.gov ID
- NCT07056023
- Acronym / sponsor ID
- EURJMT / EURJMT
- Conditions
- Intraspinal Tumor, Juxtamedullary Tumor
- Keywords
- intra-dural tumors, spinal meningioma, spinal schwannoma, spinal ependymoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital MuensterUniversity, hospital or other
- Collaborators
- Technical University of Munich, University Hospital Freiburg, Medical University of Cologne, Universitätsklinikum Hamburg-Eppendorf
- Study start
- 1 May 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary objectives: Assessment of variables leading to better outcome through regression analysis: 1. Influence of surgical approach on functionality, pain, and quality of life 2. Comparison between patient with severe neurological (McCormick scale 3-5) to patients with mild deficits (McCormick scale 1-2) 3. Role of intraoperative monitoring (IOM) in extent of resection and neurological deficits Assessment of treatment variations: 1. Assessment of risk factors for incomplete resection 2. Non inferiority of unilateral approach to achieve gross total resection of spinal meningioma, schwannoma and cauda ependymoma 3. Role of bed rest after surgery to prevent cerebro-spinal fluid leakage 4. Influence of laminectomy on cerebro-spinal fluid leakage Quality indicators: assessments of length of hospital stay, 30- and 90-days re-admissions, 30- and 90-days re-surgery, nosocomial infections
Detailed description
Introduction
- Background information Juxta-medullary tumors are mostly benign tumors in the spinal canal that may cause neurological deficits due to spinal cord or nerve root compression. The knowledge about the natural course of the disease, optimal treatment regarding timing of surgery and surgical approach are based on case series from different institutions around the world. Moreover, little is known about the long-term clinical and functional outcome after tumor resection, indicators of quality of treatment and quality of life after surgery.
Main treatment option of juxta-medullary tumors is a neurosurgical resection. The main goal of the surgery is to decompress the neuro structures in order to reveal neurological deficits. However, achieving gross total resection (GTR) is important in order to achieve long progression free survival (PFS).
Therefore, the surgeon should choose the appropriate surgical approach to achieve these goals. Several publications show that GTR, whenever possible, is essential, as subtotal resection is the main reason of tumor regrowth or recurrence. Moreover, revision surgery due to tumor recurrence is one of the main risk factors of unfavorable outcome, probably to intradural adhesions, related to the first procedure. Due to the mostly benign nature of juxtamedullary tumors, it would be very difficult to evaluate overall survival (OS) and progression free survival (PFS) within this progressive registry in the short run. For this reason, data should be kept for late cohort analysis after longer intervals. Probably up to 20 years, as previous publications reported recurrence of spinal meningioma after GTR 10 years or more after surgery.
On the other hand, too large exposure may lead to impaired recovery after surgery, eventual higher blood loss during surgery and thus longer stay in hospital (LOS) and impaired quality of life. Moreover, extensive bone resection may lead to spinal instability requiring instrumentation, during index surgery or during further follow up in case of postoperative deformity).
In addition to the oncological outcome, the neurological outcome is also very important. Depending on the localization of the tumor, its form and compression of intra-spinal structures such as the spinal cord or nerve roots many patients develop neurological deficits. Besides GTR the other goal of resection is the neurological recovery of these patients. Previous reports show that the time point of surgery is important in order to achieve full recovery. However, most of the data is derived from retrospective case series. One of the aims of this registry is to prove this hypothesis. These neurological deficits are, as mentioned above, related to the localization of the tumor within the spine, Tumors in the cervical spine would cause mainly gait ataxia, spasticity, and weakness in the upper extremities while tumors in the lumbar spine would lead to deficits in the lower extremities in combination to disturbances of bladder, bowl, and sexual functions. These functions should be evaluated and monitored, before and after treatment.
Other concerns are safety requirements in order to prevent peri-operative complications. For example, the role of intra-operative neurophysiological monitoring. Some authors recommend the utilization intra operative monitoring, however, the evidence level is very low. Other open questions are for example the utility of microscope, methods for dura closure and thrombosis prevention.
On the other hand, some tumors can be treated with irradiation, some studies showed efficacy of this method mainly in the case of Schwannomas and meningiomas. In case of residual tumor or tumor progression irradiation can be also performed to prevent further growth.
Lastly, in comparison to the methods mentioned above, a wait-and-see approach can be used for asymptomatic patients or those with mild symptoms. In this case, clinical and imaging examinations are performed at regular intervals to check the neurological status and the tumor. This can also be done for longer periods of time because of the benign nature of these tumors with the slow growth. in case of new neurological deficits of or progression surgical treatment should be advocated. Overall, it is not certain at what point therapy is indicated, especially in asymptomatic patients. Because many of these tumors are discovered by coincidence during imaging, which was performed due to other symptoms.
2 Rationale of the study The rationale of the trial is to define benchmarks on quality of life, functionality and neurological outcome after resection of juxtamedullary tumors. Furthermore, to assess and define benchmarks of quality indicators of the treatment. These measurements would be essential for future studies.
Further rationales are to find out the optimal timing, method, and approach to treat juxta-medullary tumors. Because of the low incidence of juxta-medullary tumors, a multi-center trial seems to be essential. This would allow us to analyze a large number of patients, much more than any other published paper. Moreover, the different protocols and standards approaches in each center would allow conducting Comparative Effectiveness Research (CER).
3 Aims The goal of this study is to establish a multicenter cohort of patients operated on juxtamedullary tumors. With especial emphasis on functional outcome, quality indicators (QI) and quality of life after surgery three months after surgery. Causes of unfavorable outcome should be determined.
The main hypothesis is that early and less-invasive surgery with maximal extents of resection would lead to a more favorable outcome. In the future the registry would help assessing further hypothesis can be answered on the base of comparative effectiveness research (CER), examples of these hypothesis are:
- Functional and neurological outcome in comparison to preoperative status. Comparison between Panties with good preoperative McCormick score (1-2) and those with a high preoperative score (3-5).
- Risk-factors for non-favorable outcome
- Non-Inferiority to achieve gross total resection via unilateral approaches
- Question whether laminectomy as approach may cause mor pain and impact quality of life
- Risk factors for the development of CFS Leaks
- Does bed rest prevent CSF leaks
- Does laminectomy elevate the risk of CSF leaks
- Does the utility of intraoperative neurophysiological monitoring (IOM) influence surgical outcome: rate of GTR and neurological outcome
- Rate of postoperative kyphosis and deformity in laminectomy in comparison to non-laminectomy
- Is facetectomy required for GTR of dumbbell tumors?
- Risk factors for non-complete resection
Primary outcomes are determined by:
Quality of life based on the questionnaire (EQ-D5) Extent of tumor resection (see CRF): according to surgeon: 1. Meningioma: Simpson grade 1 and 2 2. Schwannoma: complete resection, including nerve root 3. Cauda ependymoma: complete resection, including filum terminale according to postoperative MRI, 3 months after surgery 4. Other: surgeon's decision Neurological status (McCormick Score) (see CRF), 3 months after surgery Secondary Outcome Imaging: preoperative and postoperative MRI Volumetry Spinal canal occupancy ratio in %
Further patient reported outcomes:
Functionality: Neck disability index (NDI) for tumors in the cervical spine, Oswestry disability index (ODI) for tumors in the thoracic and lumbar spine (see CRF) Local and radicular pain (VAS 1-10) (see CFR) Neurological status: motor function of each limb, ataxia and gait (mJOA score) (see CRF) HADS score- based score for anxiety Questionnaire on bladder, bowl, sexual functionality
Quality indicators (QI):
Length of hospital stay 30- and 90-days readmission Nosocomial infections Blood loss Duration of surgery Progression of the disease or recurrence Other adverse events Mortality Assessment of adverse events according to Common Terminology Criteria for Adveres Events (CTCAE) 5.0 and severity according to the Ibañez scale (see CRF) CSF leakage is defined as one, when CSF leakage is identified on imaging of clinicaly and treatment is required: operative or conservative (Lumbar drain for example) Postoperative kyphosis of deformity is defined, when symptomatic (for example pain) or evident on imaging (for example kyphotic fracture on MRI) Methodology All patients treated in one of the study centers are recorded in a databank (Redcap, see below), which includes information about admission, symptoms, other diseases, treatment, quality indicators and questionnaires regarding quality of life and functionality. Data should be recorded in an anonymized in each center (see below).
For the analysis the CRF includes information about admission, surgery, discharge, and 3 months (90 days) after surgery. In addition, patients should fill out questionnaires on quality of life (EQ-D5) and functionality (ODI or NDI). Later, yearly visits can be completed to have long term results in the future regarding progression free survival (PFS) and overall survival (OS). The CRF is attached to this document.
Univariate and multivariate statistics would be applied to prove which variables might lead to a favorable or unfavorable outcome.
A minimum number of one hundred (N=100) inclusions seems to be adequate in order to perform reasonable analysis. In the event of nonsufficient recruitment, results and further recruitment would be discussed two years after initiation of the study, and annually thereafter.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults, age ≥18 years, patients treated on intraspinal, extra medullary tumor
Key inclusion criteria (2 listed)
- Adult, age ≥18 years, patients treated on intraspinal, extra medullary tumor
- Patients must have sufficient cognitive and language skills to give informed consent
Key exclusion criteria (4 listed)
- Absence of informed consent
- Lack of ability to consent
- Primary bone tumors invading the intra-spinal space
- Vertebral metastasis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of life based on the questionnaire
Time frame: prior and 3 months after resection
The EuroQol 5-Dimension questionnaire (EQ-5D) is a standardized measure of health-related quality of life. It includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each rated on 3 or 5 levels, and a visual analogue scale (EQ VAS) from 0 (worst health imaginable) to 100 (best health imaginable). Higher EQ VAS scores indicate better health status. The descriptive system can also be converted to an index score ranging typically from <0 (worse than death) to 1 (perfect health), where higher values reflect better health.
Extent of tumor resection
Time frame: 3 months after resection
1. Meningioma: Simpson grade 1 and 2 2. Schwannoma: complete resection, including nerve root 3. Cauda ependymoma: complete resection, including filum terminale according to postoperative MRI, 3 months after surgery 4. Other: surgeon's decision
Neurological status
Time frame: prior to surgery and 3 months after surgery
The McCormick Functional Classification Scale for Spinal Cord Tumors assesses functional impairment in patients with intramedullary spinal tumors. It ranges from Grade I (minimal symptoms, fully active) to Grade IV (severe disability, dependent). The scale has four grades, with Grade I as the best and Grade IV as the worst outcome. Higher grades indicate greater neurological impairment and reduced functional independence.
23 secondary outcomes
Tumor Volume
Time frame: prior to surgery and 3 months after surgery
Spinal Canal Ratio
Time frame: prior surgery and 3 moths after surgery
Functionality: Oswestry disability index (ODI) for tumors in the thoracic and lumbar spine
Time frame: prior and 3 months after surgery
Funtionality: Neck disability index (NDI) for tumors in the cervical spine
Time frame: prior surgry and 3 months after surgery
Local and radicular pain
Time frame: prior and 3 months after surgery
Neurological status
Time frame: prior and 3 months after surgery
Motor deficits
Time frame: prior surgery and 3 months after surgery
anxiety and depression
Time frame: prior and 3 months after surgery
bladder functionality
Time frame: prior and 3 months after surgery
Bowl functionality
Time frame: prior surgery and 3 months after surgery
Sexual funtionality
Time frame: prior and 3 months after surgery
Length of hospital stay
Time frame: Perioperative/Periprocedural
30-days readmission
Time frame: 3 months after surgery
90-days readmission
Time frame: 3 months after surgery
Nosocomial infections
Time frame: Perioperative/Periprocedural and 3 motnhs after surgery
estbimated blood loss
Time frame: Perioperative/Periprocedural
Duration of surgery
Time frame: Perioperative/Periprocedural"
Progression of the disease or recurrence
Time frame: 3 months after surgery
adverse events
Time frame: 3 months after surgery
Mortality
Time frame: 3 months after surgery
advers events _2
Time frame: Perioperative/Periprocedural and 3 months after surgery
CSF leakage
Time frame: Perioperative/Periprocedural and 3 months after surgery
Postoperative kyphosis
Time frame: 3 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2025.
- Individual participant dataSharing planned: Yes
Related trials for Intraspinal Tumor
Not yet recruiting
Effects of Transcranial Alternating Current Stimulation on Postoperative Anxiety in Patients Undergoing Intraspinal Tumor Resection
Postoperative Anxiety in Patients Undergoing Intraspinal Tumor Resection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intraspinal Tumor and Juxtamedullary Tumor, run by University Hospital Muenster at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michael Schwake, MD (+49 251 8343930, schwakem@uni-muenster.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of life based on the questionnaire (time frame: prior and 3 months after resection). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025; AzTrials last refreshed its copy on 8 Nov 2026.